Combining MRI and clinical data to detect high relapse risk after the first episode of psychosis.

Autor: Solanes A; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; FIDMAG Germanes Hospitalàries Research Foundation, Barcelona, Spain.; Department of Psychiatry and Forensic Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain., Mezquida G; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Barcelona Clínic Schizophrenia Unit, Neuroscience Institute. Hospital Clínic de Barcelona, Barcelona, Spain.; Centro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain.; Department of Clinical Foundations, Pharmacology Unit, University of Barcelona, Barcelona, Spain., Janssen J; Centro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain.; Department of Child and Adolescent Psychiatry, Institute of Psychiatry Mental Health, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, IiSGM, Madrid, Spain., Amoretti S; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Barcelona Clínic Schizophrenia Unit, Neuroscience Institute. Hospital Clínic de Barcelona, Barcelona, Spain.; Centro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain.; Department of Medicine, University of Barcelona, Barcelona, Spain., Lobo A; Centro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain.; Department of Medicine and Psychiatry, Universidad de Zaragoza, Zaragoza, Spain.; Instituto de Investigación Sanitaria Aragón (IIS Aragón), Zaragoza, Spain., González-Pinto A; Centro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain.; Universidad del País Vasco / EHU, Leioa, Bizkaia, Spain.; Instituto de Investigación Sanitaria Bioaraba, Vitoria-Gasteiz, Alava, Spain.; Psychiatric Department, Hospital Universitario de Alava, Vitoria-Gasteiz, Alava, Spain., Arango C; Centro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain.; Department of Child and Adolescent Psychiatry, Institute of Psychiatry Mental Health, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, IiSGM, Madrid, Spain., Vieta E; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Centro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain.; Department of Medicine, University of Barcelona, Barcelona, Spain.; Barcelona Clínic Bipolar and Depressive Disorders Unit, Institute of Neurosciences, Hospital Clínic de Barcelona, Barcelona, Spain., Castro-Fornieles J; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Centro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain.; Department of Medicine, University of Barcelona, Barcelona, Spain.; Department of Child and Adolescent Psychiatry and Psychology, 2017SGR881. Institute of Neuroscience, Hospital Clínic, Barcelona, Spain., Bergé D; Department of Psychiatry and Forensic Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.; Centro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain.; Hospital del Mar Medical Research Institute, Barcelona, Spain., Albacete A; FIDMAG Germanes Hospitalàries Research Foundation, Barcelona, Spain., Giné E; Hospital de Mataró, Barcelona, Spain., Parellada M; Centro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain.; Department of Child and Adolescent Psychiatry, Institute of Psychiatry Mental Health, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, IiSGM, Madrid, Spain., Bernardo M; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Barcelona Clínic Schizophrenia Unit, Neuroscience Institute. Hospital Clínic de Barcelona, Barcelona, Spain.; Centro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain.; Department of Medicine, University of Barcelona, Barcelona, Spain., Pomarol-Clotet E; FIDMAG Germanes Hospitalàries Research Foundation, Barcelona, Spain. epomarol-clotet@fidmag.org.; Centro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain. epomarol-clotet@fidmag.org., Radua J; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. radua@recerca.clinic.cat.; FIDMAG Germanes Hospitalàries Research Foundation, Barcelona, Spain. radua@recerca.clinic.cat.; Centro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain. radua@recerca.clinic.cat.; Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom. radua@recerca.clinic.cat.; Centre for Psychiatric Research and Education, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. radua@recerca.clinic.cat.
Jazyk: angličtina
Zdroj: Schizophrenia (Heidelberg, Germany) [Schizophrenia (Heidelb)] 2022 Nov 17; Vol. 8 (1), pp. 100. Date of Electronic Publication: 2022 Nov 17.
DOI: 10.1038/s41537-022-00309-w
Abstrakt: Detecting patients at high relapse risk after the first episode of psychosis (HRR-FEP) could help the clinician adjust the preventive treatment. To develop a tool to detect patients at HRR using their baseline clinical and structural MRI, we followed 227 patients with FEP for 18-24 months and applied MRIPredict. We previously optimized the MRI-based machine-learning parameters (combining unmodulated and modulated gray and white matter and using voxel-based ensemble) in two independent datasets. Patients estimated to be at HRR-FEP showed a substantially increased risk of relapse (hazard ratio = 4.58, P < 0.05). Accuracy was poorer when we only used clinical or MRI data. We thus show the potential of combining clinical and MRI data to detect which individuals are more likely to relapse, who may benefit from increased frequency of visits, and which are unlikely, who may be currently receiving unnecessary prophylactic treatments. We also provide an updated version of the MRIPredict software.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz: